Glulisine + Lantus in Type I Patients

• Status: Completed
• Trial end date: 2005-06-01

Summary

To evaluate the efficacy (in terms of change HbA1c from baseline to endpoint) and safety (in terms of adverse events, clinical chemistry, lipids, hematology) of insulin glulisine (HMR 1964) in subjects with type I diabetes mellitus

• Phase: Phase 3

Details

• Lead Sponsor: Sanofi